Orally dissolving tablet Levitra -a new step in the treatment of patients with erectile dysfunction
- Authors: Rasner P.I1, Pushkar D.Y.1
-
Affiliations:
- Issue: No 4 (2013)
- Pages: 93-98
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279932
- ID: 279932
Cite item
Open Access
Access granted
Abstract
Full Text
References
- Батин М. Лекарства от старости. М.: Издательство И.В. Балабанова. М., 64 с.
- Dowson A.J., Charlesworth B.R. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int. J Clin. Pract. 2003;57(7):573-576.
- Stimmel G.L., Gutierrez M.A. Counseling patients about sexual issues. Pharmacotherapy. 2006;26(11): 1608-1615.
- Perelman M, Edwards D. Perceptions of Erectile Dysfunction Therapy and Acceptance of an Orodispersible Phosphodiesterase Type 5 Drug Formulation Among Patients and Physicians. J Mens Health. 2010;7(3): 325.
- Сегал А.С., Пушкарь Д.Ю. Новый патогенетический подход, а также способ лечения и профилактики эректильной дисфункции -модулируемая эректильная оксигенация кавернозной ткани полового члена. Урология. 2004;5:48-51.
- Blount M.A., Beasley A., Zoraghi R et al. Bindingof tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol. Pharmacol. 2004;66:144-152.
- Gbekor E., Bethell S., Fawcett L. et al. Phosphodi-esterase 5 inhibitor profiles against all human phosphodiesterase families: implications for use as pharmacological tools. J Urol. 2002;167(Suppl. 4):246.
- Saenz de Tejada I., Angulo L., Cuevas P. et al. The phosphodiesterase inhibitory selectivity and the in vitroand in vivo potency of the new PDE5 inhibitor vardenafil. Int. J Impot. Res. 2001;13:282-290.
- Young J.M. Vardenafil. Expert Opin. Investig. Drugs. 2002;11:1487-1496.
- Рафальский В.В. Подходы к рациональному выбору ингибиторов фосфодиэстеразы 5 типа. Фарматека. 2004;19/20:4-8.
- Sperling H., Gittelman M., Norenberg C. et al. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J Sex Med. 2011;8(1): 261-271.
- Sperling H., Debruyne F., Boermans A et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med. 2010;7(4 Pt 1):1497-507.
- Gittelman M., McMahon C.G., Rodriguez-Rivera J.A. et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int. J Clin. Pract. 2010;64( 5): 594-603.
- SatisFACTS. Международный опрос. Байер ХелсКэр, 2011.
- Rosen R.C., Fisher W.A., Eardley I. et al. The Multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr. Med. Res. Opin. 2004;20(5) :607-617.
Supplementary files
